Trump Lowers Drug Prices – Good or Bad Idea? – Part I

 

Everyone believes drug prices are too high. Republicans and Democrats have argued for years over this issue. Democrats favor price controls, which usually lead to drug shortages, while Republicans favor market incentives, more authorization of generic manufacturers and Medicare Part D to help seniors pay for their drugs.

President Trump has just released his latest plan for lowering drug prices. Naturally, there is plenty of debate, even among conservatives, whether this plan will be helpful or harmful. Let’s take a moment to consider two points of view. But first, let’s describe the Trump plan.

The Trump Plan

Trump’s executive order bans drug-maker rebates in Medicare PartD. Drug makers negotiate rebates with pharmaceutical benefit managers (PBMs) in return for placement on formularies. Insurers use these rebates to lower premiums. However, the rebates also cause drug makers to increase their list prices, especially for products with fierce market competition like insulin. This is one reason many Americans have experienced sticker shock at the pharmacy counter in recent years.

The Trump plan also proposes benchmarking Medicare’s reimbursement rates for physician-administered drugs to an International Pricing Index (IPI); the average price paid by a group of industrialized countries. The order instructs the Health and Human Services Secretary, Alex Azar, to come up with a plan to test whether such a rule would reduce costs and improve outcomes. The order will be effective August 24th, unless the drug industry comes up with a “better plan” that Congress can enact.

The Trump plan also calls for specific lowering of insulin and epinephrine prices at Federally Qualified Health Centers (FQHCs).These centers are federally subsidized primary care clinics that serve lower-income or rural populations. Over 28 million Americans visit these clinics annually. FQHCs commonly participate in a prescription drug purchasing program known as 340B, under which providers can purchase drugs at deeply discounted rates.

Unfortunately, many providers, especially hospitals, take advantage of the 340B program to purchase drugs at low prices and then jack up the prices to patients, pocketing the difference. The Trump order ends this practice by ensuring that the prices charged to low-income uninsured patients align “with the cost at which the FQHC acquired the medication.”

Opposition to the Plan

The Wall Street Journal  editorial board opposes the Trump plan. In a recent editorial they say his prescription for change is akin to what Democrats are offering: more government control. They oppose this plan because government actuaries last summer projected it would increase premiums and out-of-pocket costs for most participants. The Congressional Budget Office (CBO) forecast the change would increase federal spending by $177 billion between 2020 and 2029.

They oppose allowing drugs to be imported from foreign countries because generics are already far cheaper in the U.S. than in Canada, and importing more expensive biologic products presents in their words, “non-trivial safety risks.” They say many novel therapies in the U.S. aren’t available in Canada because of government price controls. The same is true of most countries.

They expressed concern about the availability of new treatments if prices are reduced by government intervention. They quote the Galen Institute which reports 96% of new cancer therapies are available in the U.S. compared to 73% in Germany, 66% in France and 54% in Japan. Government price controls in the U.S. they say will reduce drug-maker spending on research and development, especially in fields like Alzeheimer’s, where experimental therapies have met with little success.

They also express fear of giving up the lead in innovation to China, which has been pouring billions into gene therapies and oncology drugs. They fear that the U.S. could become dependent on China for cancer drugs just as we are now for some antibiotics.

Lastly, they are concerned that this plan will reduce competition which is crucial to lowering prices and increasing the availability of drugs. They cite competition as the main factor responsible for consumer out-of-pocket spending staying roughly flat since 2002 even as insurance spending has tripled. They say prescription drug prices actually fell overall by 1% in 2018, the first decline since 1973.

(Next post: Support for the Trump executive order.)

Remdesivir Attacked by Progressives

Want to know how progressives would change our healthcare system? We’ve just been given a preview of Medicare for All.

Six Senate Democrats including Elizabeth Warren and Bernie Sanders sent a letter to the Department of Health and Human Services last week according to The Wall Street Journal editorial board. They are calling for price fixes for Covid-19 treatment. The six told HHS Secretary Alex Azar that the Trump Administration “acquired its supply of remdesivirat an exorbitant cost” in a deal that allows Gilead Sciences to reap “windfall revenues” that are paid “by increased premiums for American families.”

The WSJ editors say this claim is false. But is does reveal much of the left’s sweeping plan for the government to control drug prices and even pharmaceutical manufacturing.

A little background is needed. The FDA authorized remdesivir in May for emergency use in hospitals after a randomized trial showed it reduced the time to recovery on average by four days. The trial also showed a 31% decline in mortality – from 11.6% to 8% – but the study’s sample of patients was too small to make the difference statistically significant.

New data from Gilead released this month showed that severely ill patients treated with remdesivirwere 62% less likely to die than patients with similar characteristics and disease severity. A separate analysis found that 74.4% of severely ill patients treated with remdesivir recovered within 14 days compared with 59% in a control group.

HHS negotiated a deal with Gilead on June 29 that gives the U.S. 100% of Gilead’s projected production for July (94,200 treatment courses) and 90% in August and September (407,700 courses). The U.S. will pay $2,340 per course – the same price as other developed countries – but the U.S. will get treatments months earlier.

The progressive senators say the Trump Administration is paying too much, but the Institute for Clinical and Economic Review (ICER), a nonprofit often cited by liberals who say drug prices are too high, praised Gilead’s “responsible pricing decision.” ICER opined in their June review that the drug’s clinical benefits would merit a price between $4,580 and $5,080 per treatment course and between $2,520 and $2,800 after accounting for potential benefits from the steroid dexamethasone, which an Oxford trial showed significantly reduced mortality in severely ill patients.

None of this satisfies the progressives. They claim privately insured Americans will pay $860 more through higher premiums. This is highly doubtful when considering that if remdesivirshortens hospital stays by four or more days, insurers, hospitals and patients will save thousands since hospitals spend an average of $2,500 per in-patient day.

Gilead explains that private insurers will pay more because of regulations that require drug makers to give government programs a large discount off the wholesale price. This accounts for discrepancies in the prices charged to private individuals. But even though the prices paid by privately insured patients are higher, this doesn’t mean the added expense will be passed on in the form of higher premiums for the reasons mentioned above.

But pricing isn’t the only thing progressives want to control. The senators demand “legal provisions that allow it to assert control over the production and distribution of remdesivir” because taxpayers “furnished over $70 million in research costs for the drug.” They want the government to seize patents for drugs that result in part “from publicly-funded R & D” and license them to “a generic manufacturer for production at a lower cost.”

This kind of thinking fails to understand the reality of the high cost of drug development. There is a reason that the U.S. leads the world in new drug development while socialized medicine countries must suffer from unavailability of many new drugs. Gilead actually discovered and developed remdesivirover ten years ago while exploring new treatments for Hepatitis C and respiratory syncytial virus. While the drug failed to be effective in these diseases, the National Institutes of Health has since helped fund in vitro and mouse studies of remdesivir’s efficacy against emerging viruses including Ebola, MERS, SARS and now Covid-19.

NIH funding of vaccines and treatments for infectious disease is quite common because the success rate is low but the potential benefits to society are great. Only a third of vaccines and a quarter of treatments for infectious diseases are approved after entering Phase One trials. Many other beneficiaries are in developing countries where drug makers can never recover R & D costs.

Gilead has already licensed remdesivirto five generic manufacturers at no cost to make and sell in 127 developing countries. They expect their development and manufacturing costs to exceed $1 billion by the end of this year.

None of this would be possible if progressives are allowed to control drug prices and manufacturing. Americans would inevitably wait longer for new treatments, just as patients in socialized medicine countries do now. These companies would no longer have the incentives to invest billions in R & D that might never prove profitable. The WSJ sums up the situation well: “Better pray the pandemic subsides before these Democrats control the government.”

 

Republican Solutions to Winning the Healthcare Debate

 

Healthcare is once again a big issue in the presidential campaign of 2020. It ranks near or at the top of the list of concerns for most voters.

Democrats are pushing extreme changes such as Medicare for All, a single-payer socialized medicine model. Those who have backed away from this extreme want to double-down on the failed ObamaCare system. What are Republicans offering?

President Trump has made significant improvements in ObamaCare by offering short-term, limited duration plans at lower cost than the exchange plans and by allowing the formation of association health plans. He has also eliminated the dreaded Individual Mandate that forced Americans to purchase health insurance or pay a penalty tax. He is making improvements to Medicaid by giving states more flexibility to design their own plans with block-grants. (Trump Improving Medicaid) But is all this enough?

Former Louisiana Governor Bobby Jindal thinks there is more that can be done. Writing in The Wall Street Journal, Jindal identifies the biggest concerns for most Americans when it comes to healthcare. He says most people like their health insurance as it is except for:

  • High out-of-pocket drug prices
  • High Deductibles
  • Surprise Hospital bills

 

The solution is to provide what Americans really want: lower prices with minimal disruption.

To accomplish these goals, Jindal has a three-step plan:

  • Lower drug prices
  • Protect patients from surprise costs
  • Price transparency

 

Lower Drug Prices

Everyone knows Americans pay more for their drugs than most countries around the world. Many of these nations have national health systems (socialized medicine) whereby governments negotiate with drug companies directly to set prices. Democrats have responded by calling for more government intervention, either through price controls or threatening drug patents. Drug makers respond by saying such heavy-handed measures stymie drug innovation which leads to poorer health outcomes, lowered quality of life and more health costs. There is some validity to the arguments on both sides. (see Cancer Survival Best in the U.S.)

Republican efforts to address this problem have included speeding up approvals of generic drugs, limiting evergreen patent abuses, making it easier for generic companies to get product samples, and cracking down on anticompetitive agreements between brand and generic companies. Recent bills introduced in Congress would limit drug prices for products developed with federally funded research.

President Trump has recently gone further by insisting that America no longer bear a disproportionate share of drug research and development costs. He is pushing NATO to pay more toward their own defense and defending American tech companies from European tax schemes. Jindal says he should fight for the same equity in healthcare spending through trade agreements, international rules and direct negotiations.

Protect Patients From Surprise Costs

Many patients experience surprise medical costs when they use emergency medical providers like ambulances, emergency room doctors, and anesthesiologists who are out-of-network providers even though the hospital they used was in network. Today there are bipartisan bills in Congress to address this problem. Republicans should work together to find the right balance between broadening networks and arbitration to solve this issue.

Price Transparency

President Trump is already on record for pushing more price transparency in medicine. This is especially needed in hospitals and drug makers, who traditionally have obscured the true cost of their treatments from the public.  Jindal explains: “HHS aims to empower consumers to improve the drug marketplace. Price transparency would allow consumers to shop intelligently with no surprise charges and force providers to offer competitive pricing that is generally the same for each consumer.”

If Republicans can accomplish these three goals, and voters can actually see these positive improvements in their healthcare, they can win the debate over improving healthcare in the next election. If they fail, voters may make the foolish choice to believe the Democratic solutions actually make sense.